WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412106

CAS#: 969-99-3

Description: Opromazine is a traditional antipsychotic with anti-emetic activity.

Chemical Structure

CAS# 969-99-3

Theoretical Analysis

MedKoo Cat#: 412106
Name: Opromazine
CAS#: 969-99-3
Chemical Formula: C17H19ClN2OS
Exact Mass: 334.0907
Molecular Weight: 334.86
Elemental Analysis: C, 60.98; H, 5.72; Cl, 10.59; N, 8.37; O, 4.78; S, 9.57

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Opromazine; Ba-2835; Ba2835; Ba 2835

IUPAC/Chemical Name: 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, 5-oxide (9CI)


InChi Code: InChI=1S/C17H19ClN2OS/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)22(21)17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 334.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Wang Z, Fang Y, Teague J, Wong H, Morisseau C, Hammock BD, Rock DA, Wang Z. In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s. Drug Metab Dispos. 2017 Jul;45(7):712-720. doi: 10.1124/dmd.117.075226. Epub 2017 Apr 20. PMID: 28428366; PMCID: PMC5452678.

2: Li X, Yang Y, Zhou K. [Simultaneous determination of chlorpromazine and promethazine and their main metabolites by capillary electrophoresis with electrochemiluminescence]. Se Pu. 2012 Sep;30(9):938-42. Chinese. doi: 10.3724/sp.j.1123.2012.04025. PMID: 23285977.

3: Hikiji W, Kudo K, Sato S, Usumoto Y, Tsuji A, Ikeda N. False negative result for amphetamines on the Triage Drug of Abuse panel? The cause of the unusual phenomenon with experimental analyses. Int J Legal Med. 2009 May;123(3):247-52. doi: 10.1007/s00414-008-0304-9. Epub 2008 Dec 2. PMID: 19048267.

4: Minami H, Nakahara T, Miyahara A, Nakane Y. Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine. Psychiatry Clin Neurosci. 1997 Aug;51(4):217-22. doi: 10.1111/j.1440-1819.1997.tb02586.x. PMID: 9316167.

5: Dascalu A, Korenstein R, Oron Y, Nevo Z. A hyperosmotic stimulus regulates intracellular pH, calcium, and S-100 protein levels in avian chondrocytes. Biochem Biophys Res Commun. 1996 Oct 14;227(2):368-73. doi: 10.1006/bbrc.1996.1514. PMID: 8878522.

6: Miyoshi T, Yamamichi R, Maruyama T, Otagiri M. Reversal of signs of induced cotton effects of dicumarol-alpha 1-acid glycoprotein systems by phenothiazine neuroleptics through ternary complexation. Pharm Res. 1992 Jul;9(7):845-9. doi: 10.1023/a:1015880327911. PMID: 1279650.

7: Ward DJ, Krzeminska EC, Tanner NS. Treatment of toxic epidermal necrolysis and a review of six cases. Burns. 1990 Apr;16(2):97-104. doi: 10.1016/0305-4179(90)90165-s. PMID: 2140940.

8: Schoonderwoerd SA, Beijersbergen van Henegouwen GM, van Belkum S. In vivo photodegradation of chlorpromazine. Photochem Photobiol. 1989 Nov;50(5):659-64. doi: 10.1111/j.1751-1097.1989.tb04323.x. PMID: 2623051.

9: Kelder PP, de Mol NJ, Janssen LH. Is hemoglobin a catalyst for sulfoxidation of chlorpromazine? An investigation with isolated purified hemoglobin and hemoglobin in monooxygenase and peroxidase mimicking systems. Biochem Pharmacol. 1989 Oct 15;38(20):3593-9. doi: 10.1016/0006-2952(89)90132-9. PMID: 2818648.

10: Schoonderwoerd SA, Beijersbergen van Henegouwen GM, Luijendijk JJ. Photobinding of chlorpromazine and its sulfoxide in vitro and in vivo. Photochem Photobiol. 1988 Nov;48(5):621-6. doi: 10.1111/j.1751-1097.1988.tb02872.x. PMID: 3241834.

11: Miyamoto Y, Balkovetz DF, Ganapathy V, Iwatsubo T, Hanano M, Leibach FH. Effects of phenothiazines on the Na+-H+ exchanger of the brush-border membrane from the proximal small intestine of the rabbit. J Pharmacol Exp Ther. 1988 Jun;245(3):823-8. PMID: 2838606.

12: Sahaf ZY, Publicover SJ. Chlorpromazine, but not chlorpromazine sulphoxide, stimulates transmitter release from motor nerve terminals. Brain Res. 1987 Dec 29;437(2):397-401. doi: 10.1016/0006-8993(87)91660-x. PMID: 2893656.

13: Minetti M, Di Stasi AM. Involvement of erythrocyte skeletal proteins in the modulation of membrane fluidity by phenothiazines. Biochemistry. 1987 Dec 15;26(25):8133-7. doi: 10.1021/bi00399a017. PMID: 2831937.

14: Yeung PK, Hubbard JW, Korchinski ED, Midha KK. Radioimmunoassay for the N-oxide metabolite of chlorpromazine in human plasma and its application to a pharmacokinetic study in healthy humans. J Pharm Sci. 1987 Oct;76(10):803-8. doi: 10.1002/jps.2600761011. PMID: 3430345.

15: Midha KK, Hubbard JW, Cooper JK, Gurnsey T, Hawes EM, McKay G, Chakraborty BS, Yeung PK. Therapeutic monitoring of chlorpromazine. IV: Comparison of a new high-performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites. Ther Drug Monit. 1987 Sep;9(3):358-65. PMID: 3672582.

16: Sahaf ZY, Publicover SJ. Postsynaptic inhibitory effects of phenothiazines at cholinergic synapses may not involve calmodulin. Naunyn Schmiedebergs Arch Pharmacol. 1986 Aug;333(4):454-6. doi: 10.1007/BF00500024. PMID: 3490626.

17: Buettner GR, Motten AG, Hall RD, Chignell CF. Free radical production by chlorpromazine sulfoxide, an ESR spin-trapping and flash photolysis study. Photochem Photobiol. 1986 Jul;44(1):5-10. doi: 10.1111/j.1751-1097.1986.tb03556.x. PMID: 3018808.

18: Hawes EM, Hubbard JW, Martin M, McKay G, Yeung PK, Midha KK. Therapeutic monitoring of chlorpromazine. III: Minimal interconversion between chlorpromazine and metabolites in human blood. Ther Drug Monit. 1986;8(1):37-41. PMID: 3961895.

19: Fasanmade AA, Fell AF. Determination of chlorpromazine and its sulphoxide in pharmaceutical dosage forms by third-order derivative ultraviolet spectroscopy. Analyst. 1985 Sep;110(9):1117-24. doi: 10.1039/an9851001117. PMID: 4061864.

20: Nakano M, Sugioka K, Nakano H, Takyu C, Inaba H. Generation of electronically excited species during enzymatic oxidation of chlorpromazine and related compound. Biochem Biophys Res Commun. 1985 Aug 15;130(3):952-6. doi: 10.1016/0006-291x(85)91707-3. PMID: 2862870.

21: Lazo JS, Hait WN, Kennedy KA, Braun ID, Meandzija B. Enhanced bleomycin- induced DNA damage and cytotoxicity with calmodulin antagonists. Mol Pharmacol. 1985 Mar;27(3):387-93. PMID: 2579318.

22: McKay G, Cooper JK, Hawes EM, Hubbard JW, Martin M, Midha KK. Therapeutic monitoring of chlorpromazine II: Pitfalls in whole blood analysis. Ther Drug Monit. 1985;7(4):472-7. doi: 10.1097/00007691-198512000-00020. PMID: 4082244.

23: Hubbard JW, Cooper JK, Hawes EM, Jenden DJ, May PR, Martin M, McKay G, Van Putten T, Midha KK. Therapeutic monitoring of chlorpromazine I: Pitfalls in plasma analysis. Ther Drug Monit. 1985;7(2):222-8. doi: 10.1097/00007691-198506000-00015. PMID: 4024218.

24: Yeung PK, Hubbard JW, Cooper JK, Midha KK. A study of the kinetics of chlorpromazine sulfoxide by a specific radioimmunoassay after a single oral dose of chlorpromazine in healthy volunteers. J Pharmacol Exp Ther. 1983 Sep;226(3):833-8. PMID: 6887014.

25: Gillette R, Green DJ. Phenothiazines mimic the action of cAMP in potentiating slow inward current in a bursting molluscan neuron. Brain Res. 1983 Aug 29;273(2):384-6. doi: 10.1016/0006-8993(83)90868-5. PMID: 6311354.

26: Grinstein S, Furuya W. Binding of 125I-calmodulin to platelet alpha- granules. FEBS Lett. 1982 Apr 5;140(1):49-52. doi: 10.1016/0014-5793(82)80518-8. PMID: 6806121.

27: Dahl SG, Hjorth M, Hough E. Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation. Mol Pharmacol. 1982 Mar;21(2):409-14. PMID: 6124878.

28: Witman GB, Minervini N. Role of calmodulin in the flagellar axoneme: effect of phenothiazines on reactivated axonemes of Chlamydomonas. Prog Clin Biol Res. 1982;80:199-204. doi: 10.1002/cm.970020738. PMID: 6285386.

29: Barabás K, Molnár J. Lack of correlation between intercalation and plasmid curing ability of some tricyclic compounds. Acta Microbiol Acad Sci Hung. 1980;27(1):55-61. PMID: 6106347.

30: MARTIN WR, RIEHL JL, UNNA KR. Chlorpromazine. III. The effects of chlorpromazine and chlorpromazine sulfoxide on vascular responses to L-epinephrine and levarterenol. J Pharmacol Exp Ther. 1960 Sep;130:37-45. PMID: 14421747.

31: MARTIN WR, EADES CG. A comparative study of the effect of drugs on activating and vasomotor responses evoked by midbrain stimulation: atropine, pentobarbital, chlorpromazine and chlorpromazine sulfoxide. Psychopharmacologia. 1960 Jun 23;1:303-35. doi: 10.1007/BF00404228. PMID: 13767427.

32: FLANAGAN TL, LIN TH, NOVICK WJ, RONDISH IM, BOCHER CA, VAN LOON EJ. Spectrophotometric method for the determination of chlorpromazine and chlorpromazine sulphoxide in biological fluids. J Med Pharm Chem. 1959 Jun;1:263-73. doi: 10.1021/jm50004a005. PMID: 13823366.

33: ERDOS EG, BAART N, SHANOR SP, FOLDES FF. The inhibitory effect of chlorpromazine and chlorpromazine sulfoxide on human cholinesterases. Arch Int Pharmacodyn Ther. 1958 Oct 1;117(1-2):163-7. PMID: 13606923.

34: MILLICAN RC, RHODES CJ. The effects of chlorpromazine and chlorpromazine sulfoxide in normal and touriquet-shocked mice. J Pharmacol Exp Ther. 1958 Feb;122(2):262-70. PMID: 13514615.

35: DAVIDSON JD, TERRY LL, SJOERDSMA A. Action and metabolism of chlorpromazine sulfoxide in man. J Pharmacol Exp Ther. 1957 Sep;121(1):8-12. PMID: 13481822.

36: BUTLER WM Jr, MORAN NC. The pharmacological properties of chlorpromazine sulfoxide, a major metabolite of chlorpromazine; a comparison with chlorpromazine. J Pharmacol Exp Ther. 1956 Nov;118(3):328-37. PMID: 13377302.